" /> Mcleod syndrome - CISMeF





Preferred Label : Mcleod syndrome;

Symbol : MCLDS;

CISMeF acronym : MCLDS;

Type : Phenotype, molecular basis known;

Alternative titles and symbols : Mcleod phenotype; Neuroacanthocytosis, mcleod type;

Description : Hematologically, McLeod syndrome is characterized by the absence of red blood cell Kx antigen, weak expression of Kell red blood cell antigens, acanthocytosis, and compensated hemolysis. Most carriers of this McLeod blood group phenotype have acanthocytosis and elevated serum creatine kinase levels and are prone to develop a severe neurologic disorder resembling Huntington disease (143100). Onset of neurologic symptoms ranges between 25 and 60 years (mean onset 30-40 years), and penetrance appears to be high. Additional symptoms include generalized seizures, neuromuscular symptoms leading to weakness and atrophy, and cardiomyopathy mainly manifesting with atrial fibrillation, malignant arrhythmias, and dilated cardiomyopathy (summary by Jung et al., 2007). The cooccurrence of McLeod syndrome and chronic granulomatous disease (CGD; 306400) results from a contiguous gene deletion (Francke et al., 1985).;

Inheritance : X-linked;

Molecular basis : Caused by mutation in the Kell blood group protein gene (XK, 314850.0001);

Laboratory abnormalities : Elevated serum creatine levels;

Prefixed ID : #300842;

Details


You can consult :


Nous contacter.
07/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.